Day: July 28, 2020

MARIETTA, Ga., July 28, 2020 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the addition of Rohit Kashyap, Ph.D., as Executive Vice President and Chief Commercial Officer, effective August 3, 2020. Dr. Kashyap is an accomplished strategic leader with experience in building successful global businesses, and a consistent track record of delivering growth, transforming business portfolios and building high impact teams. He brings to MiMedx more than 20 years of medical device experience, with a proven history of performance in developing strategies for market creation and commercial models that deliver value to patients and healthcare systems.Timothy R. Wright, MiMedx Chief Executive Officer,...

TORONTO, July 28, 2020 (GLOBE NEWSWIRE) — Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX)(OTCQB: ENGMF)(FSE: 2AV) is excited to announce a new partnership with leading athletic tape brand, SpiderTech. The partnership will be seen across Enthusiast Gaming’s entire platform through user-generated content, and online entertainment and advertising, and extend to Luminosity Gaming (“Luminosity”) and its esports sponsorships, influencer roster, events, and media advertising, building awareness and promoting SpiderTech’s leading edge athletic tape within the gaming community.SpiderTech is the next generation in kinesiology tape: pre-cut individually packaged athletic tape applications for specific parts of the body. SpiderTech’s Gaming Gear Applications help gamers enhance their performance. The applications...

Precision medicine study designed to confirm drug’s ability to cross blood-brain barrier and hit molecular targets in high-grade glioma patients with FGFR genetic alterationsPatients with a positive PK response will continue on infigratinib after surgeryPHOENIX and SAN FRANCISCO, July 28, 2020 (GLOBE NEWSWIRE) — Ivy Brain Tumor Center at Barrow Neurological Institute announced today that the first patient has been dosed in an investigator-initiated Phase 0/2 clinical trial of infigratinib in recurrent high-grade glioma driven by FGFR genetic alterations. Infigratinib is an investigational, orally administered, FGFR1-3 selective tyrosine kinase inhibitor being developed by BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate company QED Therapeutics, Inc.The investigator-initiated Phase 0/2 trial is designed to confirm drug effects within...

NESS ZIONA, Israel, July 28, 2020 (GLOBE NEWSWIRE) — Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that Sol-Gel has been informed by its collaboration partner that the launch of an FDA-approved generic drug is expected in the second quarter of 2021. In 2019, sales of the brand name product exceeded $180 million in the United States. Per terms of the previously announced collaboration agreement, Sol-Gel will receive payments based on product sales beginning at the launch date.“We are delighted to announce the expected market entry of a second partnered generic dermatology product,” commented Alon Seri-Levy, Chief Executive Officer of Sol-Gel. “Importantly,...

SALT LAKE CITY, July 28, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that the company has launched a new enhancement that is now available on its Vectra® test report. The new test report provides an individualized estimate of a patient’s one-year risk of rapid radiographic progression (RP). The RP result in every report is personalized based on the patient’s age, gender and adiposity. “We previously presented data demonstrating that Vectra is the best single predictor of joint damage. Inclusion of information on RP risk in the Vectra test report now gives clear insight into both the patient’s current rheumatoid arthritis (RA) inflammation and the future risk of joint damage,” said Mark S. Verratti, president of Myriad Neuroscience and Myriad...

Reports Record 2Q20 US GAAP Net Income of $112.1 million or $3.83 per shareRecord Economic Operating Income of $166.9 million, or $5.69 per shareThe Nikola investment contributed $64.9 million to Economic Operating Income, or $2.21 per shareStrong Book Value Growth, up $5.82 per share to $28.96, Tangible Book Value up $5.86 to $22.94 per shareNEW YORK, July 28, 2020 (GLOBE NEWSWIRE) — Cowen Inc. (NASDAQ: COWN) (“Cowen” or “the Company”) today announced its operating results for the second quarter ended June 30, 2020.Jeffrey M. Solomon, Chair and Chief Executive Officer of Cowen, said, “We outperformed across the entire organization in the second quarter. With record revenues in our banking and markets businesses as well as a strong contribution from our investment management operations, we generated record profitability, even...

BOSTON, July 28, 2020 (GLOBE NEWSWIRE) — resTORbio resTORbio, Inc. (Nasdaq: TORC) today announced the award from the National Institute on Aging to fund a randomized, double-blind, placebo-controlled pilot study of RTB101, an investigational orally-administered potent small molecule inhibitor of target of rapamycin complex 1 (TORC1), as compared to placebo for COVID-19 post-exposure prophylaxis in older adults. The study is supported by additional data observed in resTORbio’s Phase 2b and Phase 3 clinical trials, which suggest the potential of RTB101 to reduce the severity of laboratory-confirmed coronavirus infections as previously announced.Funding of a randomized, double-blind, placebo-controlled pilot clinical study of RTB101 prophylaxis to reduce the severity of COVID-19The new clinical study is a randomized, double-blind,...

Next-generation PET tracer detects pathological alpha-synuclein with improved signal-to-noise ratioOral presentation at AAIC further demonstrates the strength of AC Immune’s Morphomer™ platform for generating highly selective small molecule diagnosticsLAUSANNE, Switzerland, July 28, 2020 (GLOBE NEWSWIRE) — AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, with a broad pipeline focused on neurodegenerative diseases, today reported new data for its next generation alpha-synuclein positron emission tomography-(PET) tracer during an oral presentation at the Alzheimer’s Association International Conference (AAIC) and anticipates advancing its lead compound toward clinical stage development in Q4 2020.The compelling preclinical results demonstrate enhanced contrast and alpha-synuclein target specificity,...

SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the Company’s second quarter 2020 financial results will be released on Monday, August 10, 2020. Company management will host a conference call on Monday, August 10, 2020 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.The press release and live audio webcast can be accessed via the Investor section of the Company’s website at www.calithera.com. The conference call can be accessed by dialing (855) 783-2599 (domestic) or (631) 485-4877 (international) and refer to conference...

AUSTIN, Texas, July 28, 2020 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced the successful completion of the fifth cohort of the ReSPECT Clinical Trial and expansion to a second clinical trial site, the UT Southwestern Medical Center in Dallas.The Phase 1 ReSPECT Clinical Trial is intended to assess the safety, tolerability, and distribution of a novel radiotherapy, Rhenium NanoLiposomes (RNL™), in adults with recurrent glioblastoma (GBM) after standard surgical, radiation, and chemotherapy treatment. ReSPECT is supported by an award from the National Cancer Institute through Phase 2 development. Glioblastoma is a rare, incurable, and fatal disease with a median survival of about nine months following recurrence despite the current standard of care.Patient screening and enrollment at UT...